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The regulation ofacid secretion was clarified by the development ofH2-receptor antagonists
in the 1970s. It appears that gastrin and acetylcholine exert their effects on acid secretion
mainly by stimulation of histamine release from the enterochromaffin-like (ECL) cell of the
fundic gastric mucosa. The isolated ECL cell of rat gastric mucosa responds to gastrin/
cholecystokinin (CCK), acetylcholine, and epinephrine with histamine release and to somato-
statin and R-a-methyl histaminebyinhibitionofhistamine release. Histamine andacetylcholine
stimulate the parietal cell by elevation of cAMP or [Ca]i by activation of H2 or M3 receptors,
respectively. These independent pathways converge to activate the gastric acid pump, the
H+,K+ ATPase. Activation is a function of the association of the ATPase with a potassium
chloride transport pathway that occurs in the membrane of the secretory canaliculus of the
parietal cell. Hence the secretory canaliculus is the site ofacid secretion, the acid being pumped
into the lumen ofthe canaliculus. The pump iscomposed oftwo subunits, a large catalytic and a
smaller glycosylated protein. This final step of acid secretion has become the target of drugs
also designed to inhibit acid secretion. The target domain of the benzimidazole class of acid
pump inhibitors is the extracytoplasmic domain of the pump that is secreting acid, and the
target amino acids are the cysteines present in this domain. The secondary structure of the
pump can be analyzed by determining trypsin-sensitive bonds in intact, cytoplasmic-side-out
vesicles of the ATPase, and it has been shown that the a subunit has at least eight membrane-
spanning segments. Omeprazole, the first acid pump inhibitor, forms a disulfide bond with
cysteines in the extracytoplasmic loop between the fifth and sixth membrane-spanning segment
and to a cysteine in the extracytoplasmic loop between the seventh and eighth segments,
preventing phosphorylation of the pump by ATP. As a result of the effective and long-lasting
inhibition ofacid secretion by the acid pump inhibitor, superior clinical results have been found
in all forms ofacid-related disease.
INTRODUCTION
Acid secretion by the stomach is a universal attribute of all vertebrates. Its
function is to aid digestion of food by allowing peptic activity, to kill prey that is
ingested live, and to help sterilize gastric contents. Hippocrates was the first to
speculate as to how the stomach carried out digestion; his idea was that the stomach
cooked the food. He had not, however, seen the constituents of haggis. The Italian
physiologist, Spallanzani, is credited with the concept that the gastricjuice dissolved,
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rather than cooked, the food. With the beginning of modern inorganic chemistry, it
was then shown, by the Frenchman, Prout, that the secretion of the stomach was
muriatic acid, HCl. The cellular origin ofgastric acid was defined in 1895, by Golgi,
the Italian microscopist, who described the expansion ofthe secretory canaliculus of
the stimulatedparietal cell. This expansionwasillustratedwithremarkable accuracy,
using a camera lucida. The concept of active transport was first enunciated in 1905,
by Overton, but then remainedlargely ignoreduntil theworkofBoyle and Conwayin
frog muscle. They were the first to show that muscle extruded sodium and accumu-
lated potassium. Their experiment was first to cool frog muscle and show sodium
accumulation and then, with rewarming, to show extrusion ofsodium and accumula-
tion of potassium [1]. Hypotheses as to the mechanism of acid secretion by the
parietal cell were already in place in the 1920s, when a redox mechanism was
conceived, following the discovery of the redox enzymes in mitochondria by Keilin
and Hartree. This concept postulated a separation of electrons and hydrogen across
the acid secretory membrane, following oxidation of a reduced substrate; the acid
was secreted and the electrons were accepted by a cytoplasmic oxidant [2].
This concept antedatedby30years Peter Mitchell's recognition that the mitochon-
drial membrane contains redox-driven electrogenic proton pumps and that it is the
collapse of the electrochemical gradient of H+ across the mitochondrial ATP
synthetase that is responsible for the synthesis of ATP. This chemiosmotic mecha-
nism was one of the great insights of modern biology. That Peter Mitchell was
suffering from ulcer disease at the time ofhis discoverywas not a coincidence [3].
The discovery ofATPbyEngelhardt in 1938 led in the 1960s to the idea that ATP,
not redox reactions, was the source of energy needed for acid secretion by the
parietal cell. The sodium pump was described in 1957 by Jens Skou, and was shown
to exchange 3Na for 2K, thus explaining the Boyle and Conway experiments [4]. The
close relationship of the sodium pump to the acid pump of the stomach was not
realized until the 1970s [5,6,7]. It remained for molecular biology to show that the
gastric acid pump had significant homology to both the ao and L subunits of the
sodium pump [8,9].
Preliminary observations on the regulation of acid secretion were described in
patients with gastric fistulas, but Pavlov described in detail the cephalic phase of
secretory regulation in his classic studies in dogs at the beginning of the twentieth
century. The presence ofthe humoral factor, gastrin, was suggested by Edkins in the
early years of this century also, and the discovery of acetylcholine by Loewi and of
histamine by Dale in the 1920s set the stage for another of the controversies
surrounding gastric function; namely, whether gastrin, acetylcholine, or, in particu-
lar, histamine were the major stimulants ofacid secretion.
Clinical interest in acid secretion relates to peptic ulcer disease. The adage "no
acid, no ulcer" has resulted in a variety of therapies designed to reduce acid
secretion. These therapies can be divided into surgical and medical methods. The
early surgical efforts at reduction of acid secretion involved total or partial gastric
resection, developed by Billroth in Vienna. This surgery thus removed the acid-
secreting part of the stomach. These procedures were improved upon by vagotomy
and then highly selective vagotomy designed to inhibit stimulation of gastric acid
secretion rather than to remove the acid-secreting gastric fundus. Most recently,
laparoscopic, highly selective vagotomy is being introduced into surgical practice, to
minimize trauma to the patient.
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Medical therapy has depended on advances in understanding ofgastric physiology
and biochemistry, and the targets were the receptor first and then the pump. The first
drug recognized to inhibit acid secretion was extract of belladonna, deadly night-
shade. The active principle in this extract is atropine, the non-selective, but potent,
muscarinic antagonist, which inhibits vagal stimulation of acid secretion. Prostaglan-
dins of the E2 subtype were, some 70 years later, also shown to inhibit gastric acid
secretion. Both of these classes of drugs have side effects that limit their use, such as
dry mouth or blurred vision in the case of atropine, diarrhea in the case of
prostaglandins. The synthesis and the description of the actions of the H2 histamine
receptor antagonists by Black, Duncan, Durant, Ganellin, and Parsons in 1971 [10]
heralded a new era in the medical treatment of peptic diseases, whereby acid
secretion could be inhibited at the receptor level with drugs that had few, if any, side
effects. The global action of the H2 antagonists on acid secretion stimulated by
histamine or gastrin resolved the controversy regarding pathways of stimulation,
showing that the action of gastrin was mediated by the release of histamine.
The variability of response to H2-receptor antagonists, and the need for more
profound inhibition in, for example, gastroesophageal reflux disease, resulted in the
development of another class of drug able to inhibit acid secretion, the acid pump
inhibitor class [11]. This short review will discuss some aspects of r-egulation of acid
secretion and some properties of the pump. It is probably correct to say that the
advances in medical therapy in the past two decades have made surgery the
exception, rather than the rule, in acid-related disease. Understanding of the
mechanisms ofthe parietal cell has allowed these therapies to evolve.
REGULATION OF ACID SECRETION
Stimulation ofAcid Secretion
In most species, acid secretion varies from a basal to a stimulated state, depending
on the digestive requirements at the time secretion is measured. Stimulation of the
parietal cell is both centrally mediated byvagal parasympathetic fibers and peripher-
ally mediated by release of histamine from the enterochromaffin-like (ECL) cell,
acetylcholine from the vagus, and gastrin from the G cell of the antrum.
Gastrin is released from the G cell due to stimulation by aromatic amino acids.
Presumably there are receptors on the G cell that bind amino acids, which, in the
bound state, produce typical activation of second messengers such as [Ca]i or cAMP.
There are also neuronal pathways that stimulate gastrin release from the ECL cell.
Somatostatin released from the D cell of antral mucosa inhibits gastrin release, as
does luminal acid. Whether the luminal acid acts directly on the G cell or only
indirectly by stimulating release of somatostatin is not clear, although current
thinking suggests that the latter is the predominant pathway.
The controversy about pathways of stimulation began with the sequencing of
gastrin by Gregory and his collaborators [12]. That advance in the early 1960s
emphasized the role of this peptide as radioimmunoassays became available. With
these methods of analysis, it was shown that meals elevate serum gastrin, and that
this elevation was sufficient to account for the stimulation of acid secretion. Hence
gastrin appeared to be the major component of the peripheral regulatory mecha-
nism. Neutralizing antibodies for gastrin inhibit meal-induced acid secretion, but
579PRINZ ET AL.
such data show that gastrin is essential, not necessarily sufficient, for stimulation of
the parietal cell by food in the stomach [13].
The synthesis and the description ofthe action ofH2 antagonists [10] altered both
the treatment of acid disease and the understanding of peripheral regulation of
secretion. It was shown, contrary to the expectations of many, that these receptor
antagonists were extremely effective inhibitors of acid secretion during pentagastrin
stimulation. Indeed, they were able even to inhibit partially secretion due to vagal
stimulation. Since neithergastrin noracetylcholinebind to theH2-receptor, it isclear
that histamine must intervene in the pathway of stimulation initiated either by
gastrin or acetylcholine. This theory justified the idea that histamine was the final
common pathway for stimulation of acid secretion, a concept perhaps more correct
than the promotion of gastrin as the final mediator. Nevertheless, this unifying
concept was still an oversimplification. For stimulation of acid secretion, there are
parallel pathways that converge onlypartiallyby the release ofhistamine.
The ECL Cell
The search for the cell responsible for paracrine secretion of histamine was only
undertaken after the action of H2-receptor antagonists was defined. Mast cells were
long known to contain histamine and to be present in the mucosa, so at first it was
thought that mast cells were the origin of the relevant histamine. It was shown,
however, that mast cells do not respond to gastrin and that, at least in the rat, the
mast cells were few and in the wrong place in the fundic mucosa. A cell, the
enterochromaffin-like cell, was then considered to be the cell that releases histamine
in response to gastric secretagogues [14].
This cell represents between 0.5 and 1 percent ofthe cell population ofthe normal
stomach. It is recognized by its size (10 jim), specific staining properties, and a
characteristic morphology. The cytoplasm includes numerous vacuoles containing
eccentric osmophilic granules. Only recently have the properties of this cell type
become accessible to direct experimentation. Figure 1 shows two cells present close
to parietal cells in a scanning electron micrograph of an isolated rabbit gastric gland
which, by size and position, are likely to be ECL cells. Purification ofECL cells from
rat can be followed quite easily byusing the characteristic uptake ofacridine orange
by the histamine-containing granules ofthis 10 ,um diameter cell (Fig. 2).
Purification of the ECL cell of the rat [15] has allowed the direct demonstration
that gastrin cholecystokinin (CCK), and acetylcholine all release histamine from this
cell. Gastrin stimulation is accompanied by a change in intracellular calcium charac-
teristic of epithelial cells, namely, a transient increase followed by steady-state
elevation. The latter is due to calcium entry, and this plateau phase is the important
determinant of histamine release. A typical calcium signal is illustrated in Fig. 3,
where both release from calcium stores and calcium entry are shown as stimulating
histamine release. In addition, there is a cAMP-dependent release ofhistamine, but
the primary physiological secretagogue responsible for elevation ofcAMP in the cell
is not known. Epinephrine, however, stimulates histamine release in the rat ECL-cell
preparation, and this release is blocked by the 3 antagonist, propranolol, and hence
in this species there is coupling of histamine release to activation of a I8 adrenergic
receptor [15]. Perhaps this class ofreceptor is responsible for stress ulceration in the
rat and also, perhaps, in man.
The histamine is stored in acidicgranules. The storage is dependent on the activity
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YA FIG. 1. A scanning electron mi-
, ,, 0f::crograph of a rabbit gastric gland,
_ =' showing the large parietal cells. Be-
tween two clusters ofparietal cell, a
small cell with the diameter ex-
pected of an ECL cell is indicated
by an arrow.
of a V-type ATP-driven proton pump, and histamine uptake is probably coupled to
H+/histamine countertransport. Histamine is released by exocytosis, stimulated by
the ligands categorized above. The histamine is likely released in proximity to
parietal cells in the rabbit, since chiefcells in thisspecies have an adrenergic, but not
a histamine, receptor [16]. Perhaps in rabbit, epinephrine is also stored in the ECL
cell. It appears also that the ECL cell has a histamine H3-receptor subtype, since H3
antagonists elevate and H3 agonists suppress gastrin-stimulated histamine release
[15]. The action ofthese H3 compounds on cat gastric mucosal acid secretion can be
explained by their action on the ECL cell [17].
The model of the function of the ECL cell in acid secretion that is emerging is
FIG. 2. A sample of the pu-
rified rat ECL-cell prepara-
tion stained with acridine
orange [15]. The dye has been
tken up and concentrated,
and the metachromatic shift
ofthe dye changes the fluores-
cence from green to red.PRINZ ET AL.
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FIG. 3. Amodel ofthe calcium release and calcium uptake in ECLcells induced
by gastrin. Shown is an intracellular calcium pool and a resting calcium level of a
cell in short-term culture. Addition of gastrin stimulates calcium release and
calcium entry, and calcium entry is maintained for as long as the hormone is
present.
shown in Fig. 4, but it must be regarded in some aspects as tentative. The target of
the histamine released from the ECLcell is the H2-receptor on the parietal cell.
TheParietal Cell
The morphology ofthis cell is also quite characteristic. It is a large, 20 ,um conical
cell, containing a large number of mitochondria, relatively sparse Golgi, and a
well-developed cytoplasmic membrane system containing the acid pump, called the
tubulovesicular complex and, at rest, a narrow infolding of the plasma membrane,
the secretory canaliculus, as described by Golgi. When the cell is stimulated, there is
loss of the tubulovesicles and a large expansion of this structure, the secretory
canaliculus, which becomes lined with slender microvilli, now containing the acid
pump (Fig. 5). In Fig. 5, the gastric H,KATPase was stained by an a subunit-specific
antibody and illustrates the change both in morphology and the location of the H,K
ATPase [18].
There are three known classes of activating receptors on the parietal cell, the
histamine, the H2-receptor, the muscarinic M3 receptor, and the gastrin receptor.
These receptors appear to have different efficacies in terms of activation of acid
secretion. There is also an epidermal growth factor (EGF) receptor, which inhibits
histamine-stimulated acid secretion. A prostaglandin EP3 receptor subtype also
inhibits histamine-stimulated acid secretion. Arecent paper has claimed that the site
ofaction ofthese secretagogues maybe the immune system in the lamina propria of
the stomach [19], but this concept is unable to explain the direct effects of stimuli
seen in single isolated parietal cells, using video imaging [21,23], nor the effects of
stimuli on gastric glands of rabbit, which have neither lamina propria nor immune
cells in the preparation.




FIG. 4. A model of the role of the ECL cell in peripheral regulation of
gastric acid secretion. Central nervous system stimulation results in
acetylcholine release, which stimulates the ECL cell to release histamine,
but acetylcholine also binds to the M3 receptor on the surface of the
parietal cell. Gastrin is released by especially aromatic amino acids and
stimulates the ECL cell to release histamine. Although a gastrin receptor
has been found on the parietalcell, evidence indicates that this receptor is
unable to stimulate acid secretion directly.
As has been discussed for the ECL cell, there are two second messenger pathways
with elevation ofeither cAMP or[Ca]i. Histamine binds to the H2-receptor, a typical
seven-membrane segment G protein-coupled receptor [20], with a resultant eleva-
tion ofcAMP as the major second messenger. There is also an elevation of[Cali that
is of unknown significance in the histamine pathway [21]. Coupling to cAMP
elevation isvia aGsprotein, coupling tochanges of[Ca]iispresumablyby aGq orGII
complex, but this theory has not been experimentally established.
Acetylcholine binds to an M3 muscarinic receptor with transient elevation of[Cali
and then a steady-state elevation of [Ca]1i [22,23]. It appears to be the latter phase
that is responsible for stimulation of acid secretion [23]. The M3 receptor is coupled
tophospholipase C for activation ofthe transient calcium release pathway, and to an
unknown pathway for calcium entry. These two pathways are determined by two
states of the M3 receptor. One state, resulting in calcium entry, depends on a
high-affinity acetylcholine binding site; the other is lower affinity by about one order
of magnitude and appears coupled to release of calcium from intracellular stores
[23]. The releasepathway is activated at higher concentrations ofmuscarinic agonist,
and it is conceivable that the high level of [Cali that occurs after phospholipase C
(approximately 1,000 nM) activation is inhibitory and shuts offthe stimulatory effect
ofthe steady-state elevation of[Ca]i (approximately 200 nM).
Gastrin also has a receptor on the parietal cell, again a seven-membrane segment
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FIG. 5. An electron micrograph ofa resting (left) and stimulated (right) parietal cell, stained with a
monoclonal antibodyagainst the asubunit ofthe H,KATPase [18]. It canbe seen thatthe restingcell
has the pump present in cytoplasmic tubulovesicles; in the stimulated cell, the pump is present in the
microvilli lining the expanded secretory canaliculus.
G protein-coupled receptor, which results, as for the ECL cell, in elevation of[Ca]l
[24]; however, the role ofthis receptor in activation ofacid secretion is controversial.
On its own, it appears to be the weakest of the three in terms of stimulation. The
claim has been made that gastrin activation of acid secretion requires cAMP
elevation and that gastrin can potentiate either acetylcholine or histamine stimula-
tion. The role of the gastrin receptor on the parietal cell remains controversial. A
model ofthe receptors and theirpathways is shown in Fig. 6.
The various ligands that stimulate the parietal cell converge to activate the acid
pump. Alongwith and accompanying this activation isthe morphological transforma-
tion, whereby the secretory canaliculus of the cell expands as a function of a large
increase of the microvilli lining this infolding of the apical plasma membrane of the
cell (see Fig. 5).
THE ACID PUMP
Function ofthe Pump
The acid pump ofthe parietal cell has been shown to be the H,KATPase, which is
a member of the phosphorylating class of ion transport ATPases. The enzyme is a
heterodimer [25], with a catalytic or a subunit composed of about 1,000 amino acids
and a glycosylated a subunit of about 300 amino acids. Hydrolysis of ATP results in
ion transport; the chemical reaction, hydrolysis ofATP, is scalar and is converted to
vectorial ion transport byconformational changes induced in the protein. The overall
transport reaction is the electroneutral exchange of cytoplasmic H+ for K+ [6]. In
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FIG. 6. A model of the receptors on the pari-
etal cell and their second messenger pathways.
Three activating receptors are illustrated. The
major effect is exerted by activation of the hista-
mine 2 receptor, which activates adenylate cy-
clase. Acetylcholine, by binding to the M3
receptor, results in changes in [Ca]i. The changes
in [Ca]1 due to gastrin appear not to be related
directly to acid secretion.
fact, the forward H+ transporting steps and the countertransport of K+ are both
electrogenic. For the pump to function, potassium must be supplied to the extracyto-
plasmic surface. Therefore, when associated with a potassium chloride pathway in
the canalicular membrane which allows potassium chloride efflux from the parietal
cell, the pump is activated, which results in secretion of hydrochloric acid at the
expense ofATP breakdown.
AtpH 8, the pump is able to use Na+ as a surrogate forprotons, suggesting that the
transported species is not the hydrogen but the hydronium ion, H3O+ [26]. There has
been considerable speculation that H+ transport across biological membranes is by
means of a pathway specialized for the transport of protons, a proton wire. For
example, a chain of serine OH groups in a protein would form such a proton wire.
Na+ could not move along such a chain. Since Na+ is transported by the gastric
ATPase, it isprobably a conventional cation transportpathway that is involved, not a
"6proton wire." Indeed, the idea thatH-3O+ istransported allows release ofthis cation
in the same way as Na+ is released by the sodium pump without invoking specialized
alterations ofthe pKa ofcarboxylic acids in the ion binding site ofthe pump.
The parietal cell secretes acid by virtue of activation of the H+K ATPase. The
steps involved in activation include the morphological transformation of the cell,
whereby the pump moves from a cytoplasmic location in tubulovesicles to the
membrane ofthe secretory canaliculus. The activity ofthe pump is determinedbythe
access ofK+ to the extracytoplasmic surface ofthe pump [6]. In the absence ofK+ on
this surface of the pump, the pump cycle stops at the level of phosphoenzyme. The
potassium ion is required at this surface ofthe pump in order to allow dephosphory-
lation to occur. Hence an additional step of the activation process is activation of
potassium and chlorine transporters in the pump-containing membrane (Fig. 7).
The Site ofAcid Secretion
The morphological transformation discussed above has been illustrated in Fig. 5,
where, on the left, is a resting parietal cell stained with a monoclonal antibody
against the H,K ATPase ot subunit. It can be seen that the majority of the pump is
located in the cytoplasmic tubulovesicles. On the right-hand side of Fig. 5, a
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FIG. 7. A model of the biosynthesis and activation of the H,K ATPase
in the parietal cell. The two subunits are synthesized on the endoplasmic
reticulum and move through the Golgi complex to form the mature
tubulovesicles, where the pump is present as a heterodimer. Stimulation
results in formation of the microvilli of the secretory canaliculus, and the
pump is now associated with the potassium chloride pathway. Loss of
stimulus results in retrieval ofthe pump. Shown also is degradation ofthe
pump, and the balance between synthesis and degradation gives an
effective half-life ofabout 30 hours.
stimulated parietal cell is illustrated, stained with the same antibody. It is evident
that the pump is now located in the microvilli lining the secretory canaliculus.
Acridine orange staining ofthe parietal cell in rabbit gastricglands has shown that
the final location of acid secretion is in the secretory canaliculus, as predicted by
Golgi [27]. This observation does not define the site of initiation of acid secretion.
Fluorescence microscopy does not have sufficient resolution to enable detection of
acidity in tubulovesicles, so this approach leaves unanswered the question as towhen
the association occurs between the pump and the potassium chloride pathway.
In order to detect the site ofacid secretion, we take advantage ofthe properties of
omeprazole, a clinically useful inhibitor ofthe H,KATPase. Its mechanism ofaction
is illustrated in Fig. 8. It is a weak base ofpKa = 4. Hence it will concentrate in acid
spaces of less than pH 4. The only space in the body (or in rabbit gastric glands in
vitro) that has a pH less than 4 is the acid space ofthe secretingparietal cell. Once in
an acid environment, omeprazole is converted in an acid-catalyzed reaction to a
cationic sulfenamide as illustrated in Fig. 8. This sulfenamide is a permanent cation
and is therefore relativelymembrane-impermeable. Sulfenamides react with protein
thiols to make stable, covalent disulfides. In the case ofthe parietal cell and the H,K
ATPase, the sulfenamide generated from omeprazole reacts exclusively with the
thiols of the ot subunit of the H,K ATPase [28]. In fact, given its positive charge, the
sulfenamide reactsonlywith the thiols accessible from the acid space, those available
in the extracytoplasmic domain of the enzyme. Since this product is a stable covalent
derivative that can form only in acid spaces, it is possible to use electron microscopic
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FIG. 8. The pathway of activation of omeprazole. The compound accumulates in acid due to
protonation, converts to the cationic sulfenamide in an acid-catalyzed reaction, and the sulfenamide
reacts with the cysteine SH groups of the catalytic subunit that are exposed to the luminal surface of the
pump.
autoradiography to determine the site ofstimulation of acid secretion, by determin-
ing the site ofbinding ofomeprazole.
Rabbit gastric glands are made relatively non-secreting by treatment with the H2
antagonist, cimetidine. At zero time, omeprazole is added, along with a stimulant
such as cAMP. At different times, the glands are sampled, fixed, and processed for
electron microscopic autoradiography. The silver grains over the parietal cells are
allocated either to a cytoplasmic, canalicular, ornuclearcompartment. As illustrated
in Fig. 9, increase of radioactivity over the first ten minutes is found essentially only
over the canalicular compartment. Ifactivation occurred while the pump was still in
the tubulovesicular compartment, an increase of radioactivity would have been
found first in this compartment, not in the canalicular compartment. This finding
gives direct evidence that acid secretion starts only upon insertion of the pump into
the canalicular membrane [29].
The implications as tothe location ofactive potassium chloride transporters is that
they are present only in the canalicular membrane. If activation were possible while
the pump was in the cytoplasmic compartment, the cell would face the risk of
cytoplasmic acidification, since with continued hydrochloric acid secretion there
would be the possibility ofintracellular lysis ofhighly acidicparticles.
The K+ and Cl- transporter(s) could be present only in the canalicular membrane,
or the K+ transporter in the vesicle membrane and the Cl- transporter in the
canalicular membrane, or both in a separate vesicle population. Alternatively, active
cAMP or calcium-dependent kinases might be bound to the canalicular membrane
and not present in the cytoplasm. The data presented do not distinguish between
these possibilities. The resting pump membrane, however, possesses neither a C1-
nor a K+ conductance [6].
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FIG. 9. The distribution of omeprazole binding in cells following stimulation of acid secretion [29].
Gastric glands were inhibited by cimetidine, and then a batch was stimulated by cAMP, and 3H
omeprazole added at zero time. Samples were taken at the times indicated and the location of the
omeprazole determined by electron microscopic autoradiography.
The Secondaty Structure ofthe H,KATPase
Transport by this class of enzyme is thought to be a result of conformational
changes during the cycle of phosphorylation and dephosphorylation such that the
affinity and sidedness of the ion binding sites change. Thus, in the proton transport
direction for the H,K ATPase, the B1 conformation binds the proton or hydronium
ion from the cytoplasmic side at high affinity. With phosphorylation, the conforma-
tion changes to the E2P form, which has low affinity for H+ and high affinity for K+
from the extracytoplasmic face of the pump, allowing release of H+ and binding of
K+. With dephosphorylation, the E1K conformation is produced, with a low affinity
for K+ with release of K+ to the cytoplasmic side, allowing rebinding of H+. Hence
pumping is the result of cycling between the B1 and B2 forms of the enzyme [30].
Figure 10 illustrates the kinetically defined steps ofthe pump cycle. Definition ofthe
changes in pump structure during the conformational changes is a major goal of
current research.
A description ofion transport by these pumps must come, in part, from knowledge
ofthe membrane-spanning segments ofthese pumps, because ions must traverse the
structure formed by the segments. Since these parts ofthe protein are inserted in the
hydrophobic phase of the bilayer, there must be pathways allowing the passage of
charged ions within the protein segments.
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FIG. 10. The catalytic cycle of the H,K ATPase, as deter-
mined by the kinetics of phosphorylation and dephosphoryla-
tion. The pump starts its cycle with the binding site for the
proton exposed to the cytosolic face, where the ion binds with
high affinity. Phosphorylation thenforms the E1P-Hform,which
converts to the E2P-H form, nowwith the hydrogen binding site
(H30+) exposed to the exterior. Release of the hydronium is
accompanied by the binding of potassium to form the E2P-K
form, which dephosphorylates to the E2K form. The E2 form
therefore has its ion binding sites exposed to the luminal face of
the pump. The E2Kform then converts toE1 to restart the cycle.
The secondary structure of the EP-type ATPases has been deduced largely from
hydropathy plots. These plots have been interpreted variously. It has been suggested
that the a subunit has eight to ten membrane-spanning segments, whereas the a
subunit is considered to have only a single segment. In the case ofthe Na,KATPase,
the first pair of hydrophobic segments long enough to be membrane-spanning in a
helical form, H1 and H2, have been shown tobe indeed membrane-spanning byvirtue
of the fact that this region of the enzyme determines the ouabain binding affinity of
the Na,K ATPase [31], ouabain being an extracytoplasmic inhibitor of the sodium
pump. The protease resistance ofthe 19 kDa C-terminal portion ofthe a subunit of
this enzyme has been taken to mean that it is largely membrane-embedded [32], and
therefore has six membrane segments. In the case ofthe Ca ATPase ofsarcoplasmic
reticulum, it has been shown that antibodies against the region containing residues
878 to 890 react with the extracytoplasmic face of the enzyme. This region would
correspond to the loop between M7 and M8 in the originally proposed model. The
calmodulin binding domain of the Ca ATPase of plasma membrane must be cyto-
plasmic and is in the C-terminal region of this enzyme, which has led to a ten-
membrane segment-spanning model for this enzyme [33].
In the case of the gastric H,K ATPase, various lines of evidence have been
gathered to substantiate the model of Fig. 11, an eight- or ten-membrane-spanning
model for theat subunit.
Tryptic cleavage of intact, inside-out vesicles of the ATPase at a 1:4 enzyme-to-
protein ratio, followed by SDS solubilization of the residual membranes, theoreti-
cally should yield the membrane-spanning pairs. Labeling the SH groups present in
this fraction with fluorescein maleimide allowsvisualization ofthe segments present.
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FIG. 11. A model ofthe secondary structure ofthe a subunit ofthe pump, illustrating eight and perhaps
ten membrane-spanning segments, along with the site of binding of the potassium competitive inhibitor
SCH28080 and the sites ofbinding ofomeprazole.
As illustrated in Fig. 12, fluorescent segment pairs were found corresponding to Hi
through Hg. The Hg and H1o sequences were, however, absent after digestion and
washing, indicating that perhaps these sequences were not membrane-spanning or
that the cysteines were not available for labelingbyfluorescein maleimide [28].
A molecular biological approach has provided evidence that the Hg and HIo
segments are able to traverse the lipid bilayer. Here a construct was made ofmRNA
where the N-terminal part of the a subunit was interrupted by an insert containing
either Hg or Hg and H1o message, followed by the C-terminal part of the P subunit,
which contains seven potential glycosylation sites. If Hg was present in an in vitro
translation system with dog microsomes, glycosylation of the product was observed,
showing that Hg crosses the microsomal membrane, allowing glycosylation of the 13
subunit to occur. ThusHg can act as a signal transfer sequence. WhenHgand Hlo are
inserted into the mRNAconstruct, noglycosylation isobserved, showing thatHlocan
act as a stop transfer sequence, characteristic of the second of a pair of membrane-
spanning segments [34]. The model illustrated therefore shows the presence of an
H,KATPase alphaSUBUNIT
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FIG. 12. The membrane segments
of the pump as determined by tryptic
hydrolysis, separation of the mem-
brane-retained segments, labeling
these with fluorescein maleimide after
solubilization, and runningon SDSgels
[28,37]. The labeled bands were se-
quenced and represent the eight first
membrane-spanning segments of the
catalytic subunit.
additional pair of segments, not found by the biochemical methods we have em-
ployed [28].
Hence these approaches provide direct evidence for an eight- and perhaps a
ten-membrane-spanning model. It may be noted that these segments correspond
closely to the segments proposed for the Ca ATPase, but do not correspond to the
eight segments originally suggested by analysis ofhydropathy ofthe H,KATPase [7].
InhibitorSites on theH,KATPase
Since this ATPase is responsible for acid secretion and is, indeed, the "final
common pathway" and acid is a sine qua non for upper gastrointestinal ulcer
diseases, various types of compounds have been and are being developed for
treatment ofthese diseases. These compounds maybe classified into K+ competitive
and covalent types.
K+ Competitive A typical K+ competitive ATPase inhibitor, the aryl quinoline,
MDPQ, is illustrated in Fig. 13. It is a N-containing heterocyclic compound like the
imidazopyridine, SCH28080. The effect of this class of compound is exerted on the
extracytoplasmic face of the pump [35]. Using a photoaffinity analog of SCH28080,
MeDAZIP+, it has been shown that binding occurs at the extracytoplasmic loop
between M1 and M2, the same region that binds ouabain in the Na,K ATPase [36].
Molecular modeling studies argue that these compounds dock at phe'24 and asp136.
This finding also provides direct evidence for the extracytoplasmic location of the
binding site between M1 and M2.
Using MDPQ as a fluorescent probe of conformation, it was found that fluores-
cence was increased upon the addition ofATP in the presence ofmagnesium, due to
the formation of an E2P'[I] conformation of the enzyme [37]. This finding can be
interpreted as due to an increase in the hydrophobicity ofthe environment ofthe K+
competitive inhibitor. The binding site is calculated to be at the interface between
the phospholipid head groups and the fatty acids of the bilayer, which implies that
part of the conformational change involved in transport is tilting of the helices
forming Ml and M2-
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Another fluorescent probe, fluorescein isothiocyanite (FITC), has been shown to
bind to the cytoplasmic domain atJyS516. WhenNaH is added, the environment ofthis
probe becomes more hydrophobic as a function offormation ofthe El-Na conforma-
tion. The addition of K+ decreases fluorescence as a function of the E2-K conforma-
tion. The changes can be interpreted as a reciprocal conformational change of the
cytoplasmic domain and the extracytoplasmic domain betweenMl and M2during the
transport cycle.
Hence these fluorescent data suggest membraneward movement of the large
intracellular loop of the protein between 114 and H5 in the Bl direction and
membraneward movement ofthe extracytoplasmic region between Ml and M2 in the
E2direction. Other parts of the extracytoplasmic face can also be involved as
indicated by the effects ofbinding of the covalent class of pump inhibitor discussed
below.
Covalent Inhibitors There are a variety of these inhibitors on the market or
under development for treatment ofulcer disease. Omeprazole was the first ofthese
compounds developed for clinical use, and lansoprazole and pantoprazole are very
similar in structure [38]. Their general mechanism has been illustrated above. From
this information, it can be deduced that these compounds react on the extracellular
face ofthe enzyme with available cysteines.
Tryptic hydrolysis and mapping ofthe cysteines reacting with omeprazole showed
that cysteine 813 and/or 822 react as well as cysteine 892, whereas an analog,
pantoprazole, reacts only with cysteine 813 and/or cysteine 822, to give the same
inhibition [28,38]. The cysteines 813 and 822 are predicted to be in or between M5
and M6 and the cysteine 892 in the large extracytoplasmic loop between M7 and M8,
as illustrated in Fig. 11.
Thebindingofthecationicsulfenamide derivedfromomeprazole blocksphosphor-
ylation and ATPase pNPPase activity, as if the enzyme were locked into an E2[I]
configuration. This findingwould argue that motion ofthe M5/M6 region is also part
ofthe conformational changes involved in transport.
Depending on the compound used, it appears that one or both of the cysteines at
813 and 822 react. It is probably these, rather than the cysteine 892, thought to be
distant from membrane interface, that determine the inhibitory effect ofomeprazole
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TABLE 1
H2-Receptor Anatagonists and Acid Pump Inhibitors
Similarities Differences
Reversible inhibition ofacid secretion Molecular target
No side effects Efficacy and duration ofaction
Few adverse reactions Effective in GERD,NSAID
Hypergastrinemia Effective with single antibiotic in H.pylori eradication
Effective in duodenal ulcer, gastric ulcer
and its analogs. For example, pantoprazole reacts only with the cysteines in the
M5/M6 region, but has an identical inhibitory action on the H,K ATPase [38]. The
binding of pantoprazole alters the tryptic cleavage pattern of the enzyme, whereby
the major site of tryptic cleavage at the N-terminal end of the M5 segment moves
from position 776 to position 792. Hence the binding ofpantoprazole to cysteine 822
alters the conformation of this segment of the protein, another example of a
conformational change in a membrane-spanning segment ofthe pump.
ClinicalImplications
H2-receptor antagonists have been in use for many years, with excellent results in
the treatment of duodenal ulcer, good results in gastric ulcer, and good results in
mild reflux disease. It would seem, however, that the multiplicity of pathways
available to the parietal cell for acid stimulation prevent these compounds from
reliably reducing acid secretion to levels optimal for the healing of acid-induced
damage in gastric ulcer, severe reflux disease, non-steroridal anti-inflammatory
drugs (NSAID)-induced ulcers and, of course, in Zollinger-Ellison syndrome. In
contrast, the acid pump inhibitor class of drug is insensitive to the nature of the
stimulus and with covalent reaction gives long-lasting effective inhibition of acid
secretion. These drugs are therefore able to optimize the pH of either lumen or
gastricwall so as to achieve the most rapid healing available with a single modality of
therapy. It is interesting to compare the properties of the two classes of compound,
as given in Table 1, where similarities and differences are shown. Both sets ofdrugs
have not onlyderived from abetter understandingofacid secretion, but have in their
turn contributed to understanding ofgastric physiology and biochemistry.
SideEffects ofDownregulation ofAcid Secretion
The introduction of H2-receptor antagonists, while revolutionizing medical ther-
apy of ulcer disease, led initially to concerns about the effects of acid suppression.
For example, bacterial overgrowth ofthe stomachwas thought tobe a possible result
of H2-receptor antagonist treatment, bacterial overgrowth then leading to nitrosa-
mine production. Nitrosamines are carcinogens. These fears turned out to be
unjustified, and the H2 drugs are safe and effective compounds.
The introduction of omeprazole as the first acid pump antagonist led to further
fears that the compound was a carcinogen. This apprehension was based on the
finding that, in long-term, pre-clinical studies in rats, after twoyears' treatment, ECL
carcinoids (i.e., nests of ECL cells) were found in the gastric mucosa. A variety of
studies have shown that elevation of gastrin it is a necessary condition for the
development ofthese carcinoids, and that it is the hypergastrinemia induced by acid
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FIG. 14. A figure summarizing the
various experiments performed to show
that the carcinoid induction in rats by
omeprazole is due to the severe hyper-
gastrinemia induced in this model, and
not to direct action ofomeprazole [38].
Henceanymaneuverswhichreduce acid
secretion, benzimidazoles, ranitidine,
fundectomy, increase gastrin and ECL-
cell growth; maneuvers such as antrec-
tomy,whichreducegastrinlevels, inhibit
these effects.
suppression in the presence of food that results in the carcinoids in the rat. For
example, high-dose ranitidine produced the same number of carcinoids as did
omeprazole [39]. An illustration summarizing the various studies that influenced
ECL-cell growth is presented in Fig. 14. More recently, it has been possible to show
that gastrin administration to rat ECL cells stimulated cell growth as measured by
incorporation ofthethymidine analog,bromo-deoxyuridine [15]. These datasubstan-
tiate thegastrin mechanism for induction ofECL-cell hyperplasia in vivo.
Long-term surveillance of a group of about 140 patients treated with high-dose
omeprazole for seven years has shown omeprazole not to have a likelihood in man
for the development ofcarcinoids. As forthe H2antagonists, adverse eventswith this
drug are also rare.
THE FUTURE
The medical control ofacid secretion has advanced considerably in thiscentury. In
terms of receptor antagonists, the relatively ineffective, nonspecific muscarinic
antagonist, atropine, has been replaced by the selective, more effective, H2 antago-
nists. In turn, these substances are being replaced by the selective, more efficacious,
acid pump inhibitors such as omeprazole or lansoprazole. Further development of
the K+ competitive inhibitor is continuing, but perhaps acid secretory control has
reached its zenith, and focus will shift to improved healing of ulcer disease and
prevention ofdisease byeradication ofH.pylon.
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